Abstract
Apoptosis of T-lymphocytes is a fundamental process regulating antigen receptor repertoire selection during T cell maturation and homeostasis of the immune system. It also plays a key role in elimination of autoreactive lymphocytes. Resting mature T cells are activated by antigen to elicit an appropriate immune response. In contrast, preactivated T cells undergo activation-induced cell death (AICD) in response to TCR triggering alone. Thus, death by apoptosis is essential for function, growth and differentiation of T-lymphocytes. This review focuses on apoptosis mechanisms involved in T cell development and during the course of an immune response.
Keywords: T cell Apoptosis, Immune Response, CD95 SIGNALING PATHWAY, THYMOCYTE SELECTION, DEATH RECEPTORS, Death domain, FLICE inhibitory protein
Current Molecular Medicine
Title: Regulation of T cell Apoptosis during the Immune Response
Volume: 2 Issue: 3
Author(s): Sven Baumann, Andreas Krueger, Sabine Kirchhoff and Peter H. Krammer
Affiliation:
Keywords: T cell Apoptosis, Immune Response, CD95 SIGNALING PATHWAY, THYMOCYTE SELECTION, DEATH RECEPTORS, Death domain, FLICE inhibitory protein
Abstract: Apoptosis of T-lymphocytes is a fundamental process regulating antigen receptor repertoire selection during T cell maturation and homeostasis of the immune system. It also plays a key role in elimination of autoreactive lymphocytes. Resting mature T cells are activated by antigen to elicit an appropriate immune response. In contrast, preactivated T cells undergo activation-induced cell death (AICD) in response to TCR triggering alone. Thus, death by apoptosis is essential for function, growth and differentiation of T-lymphocytes. This review focuses on apoptosis mechanisms involved in T cell development and during the course of an immune response.
Export Options
About this article
Cite this article as:
Baumann Sven, Krueger Andreas, Kirchhoff Sabine and Krammer H. Peter, Regulation of T cell Apoptosis during the Immune Response, Current Molecular Medicine 2002; 2 (3) . https://dx.doi.org/10.2174/1566524024605671
DOI https://dx.doi.org/10.2174/1566524024605671 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond
Clinical Cancer Drugs New Developments and Prospective Applications for β (1,3) Glucans
Recent Patents on Biotechnology Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Thrombocytopenia in HIV Disease: Clinical Relevance, Physiopathology and Management
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets Lipoamino Acid Prodrugs of Paclitaxel: Synthesis and Cytotoxicity Evaluation on Human Anaplastic Thyroid Carcinoma Cells
Current Cancer Drug Targets Oral Candidosis in HIV-Infected Patients
Current HIV Research (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry New Perspectives of HIV/AIDS Therapy Study
Recent Patents on Anti-Infective Drug Discovery Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design